Corrigendum to “Gene expression profiling in breast cancer: A clinical perspective” [The Breast 22 (2013) 109–120]
Grazia Arpino(University of Naples Federico II), Luigi Dogliotti(Aarhus University Hospital), Fabio Puglisi(University of Udine), Daniele Generali(University of Trieste), Alberto Bottini(University of Genoa), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giorgio Mustacchi(University of Trieste), PierFranco Conte(University of Padua), P. Pronzato(Accademia Nazionale dei Lincei), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Anna Sapino(Candiolo Cancer Institute), Mario Martinotti(Istituti Ospitalieri di Cremona), Andrea Antonelli(Hospital General Universitario Morales Meseguer), Alfredo Berruti(Surgical Specialties (Canada)), Mariarosa Cappelletti(Istituti Ospitalieri di Cremona), Vanessa Zanoni(Istituti Ospitalieri di Cremona)
Cited by 2
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
|Journal of Clinical Oncology|2005|1.9k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k